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econdary Stroke Prevention With Antiplatelet
herapy With Emphasis on the Cardiac Patient
Neurologist’s View
ames M. Gebel, JR, MD, MS
ouisville, Kentucky
The prevention of secondary vascular events is of paramount importance in patients with a
history of stroke or transient ischemic attack (TIA). Most cardiologists are aware of the
benefits of clopidogrel plus aspirin versus those of other antiplatelet regimens in patients with
acute coronary syndrome. Using a representative post-stroke patient as an example, this article
reviews data evaluating the effectiveness of antiplatelet regimens in preventing secondary
vascular events in stroke and TIA patients. These results differ from those seen in clinical
trials of acute coronary syndrome patients. Clinical studies provide little evidence that
clopidogrel, with or without aspirin, is more efficacious in this setting than aspirin alone.
Moreover, the increased risk of bleeding episodes with clopidogrel and aspirin in combination
probably outweighs any small reductions in secondary event risk. In contrast, extended-release
dipyridamole (ER-DP) plus aspirin reduces secondary stroke risk to a significantly greater
extent (23% relative risk reduction) than aspirin alone. Currently available clinical trial data
support the use of ER-DP plus aspirin, but not clopidogrel plus aspirin, to prevent secondary
vascular events after stroke or TIA. (J Am Coll Cardiol 2005;46:752–5) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.058American College of Cardiology Foundation
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sne of the important considerations in the management of
atients with symptomatic cardiovascular disease (CVD) is
he prevention of secondary events. The risk of secondary
vents after stroke or acute myocardial infarction (AMI) is
igh, and reducing this risk requires careful attention to
oth nonpharmacological and pharmacological approaches.
his article focuses solely on the use of antiplatelet medi-
ations in stroke and transient ischemic attack (TIA)
atients for secondary vascular event prevention. It empha-
izes the differences in the type of recurrent vascular events
uch patients face as compared with AMI patients. Further-
ore, this report compares the efficacy and safety of various
ntiplatelet drug regimens in these populations.
Consider as a representative patient a 75-year-old man
ith a recent (within one week) ischemic stroke and a
istory of AMI (14 months before). In addition to continu-
ng standard therapy for dyslipidemia (atorvastatin), the
ttending neurologist prescribed an aspirin plus extended-
elease dipyridamole (ER-DP) combination as an antiplate-
et regimen. The patient’s cardiologist, citing the previous
MI and presumed existing coronary artery disease (CAD),
tated that he would like the patient’s antiplatelet therapy
witched to clopidogrel plus aspirin, or at least to clopi-
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004, accepted April 13, 2005.ogrel alone. What is the clinical trial evidence for and
gainst this switch in therapies?
LINICAL TRIALS OF ANTIPLATELET REGIMENS
wo large clinical trials are frequently cited in support of
lopidogrel as an antiplatelet agent appropriate for preven-
ion of secondary events in all forms of CVD: the Clopi-
ogrel versus Aspirin in Patients at Risk of Ischemic Events
CAPRIE) study (1), and the Clopidogrel in Unstable
ngina to prevent Recurrent Events (CURE) study (2).
The CAPRIE study was a large (19,185 patients at 384
linical centers) randomized, blinded study that compared
he efficacy of clopidogrel versus aspirin in preventing
ecurrent vascular events in patients who had suffered a
ecent AMI, recent stroke, or symptomatic peripheral artery
isease (PAD). Patients were randomized to either aspirin
325 mg once daily) or clopidogrel (75 mg once daily) for a
ean follow-up of 1.91 years. The primary end point was
isk of nonfatal MI, ischemic stroke, or vascular death. The
ate of the composite outcome per year was 5.32% for
lopidogrel and 5.83% for aspirin, or an 8.7% relative risk
eduction (RRR) (p  0.043) favoring clopidogrel (1).
However, the comparative efficacy of clopidogrel varied
harply by index event. The greatest (and most significant)
ifference between clopidogrel and aspirin was observed for
he PAD group (RRR for clopidogrel vs. aspirin, 23.8%; p
0.0028). In the stroke group, the advantage for clopi-
ogrel was much smaller (RRR 7.3%) and not statistically
ignificant (p  0.28). In the AMI group, aspirin had
reater efficacy, although the difference once again was not
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September 6, 2005:752–5 Secondary Stroke Preventiontatistically significant (RRR 3.7%; p  0.56). These
esults suggest greater efficacy for clopidogrel as compared
ith aspirin after symptomatic PAD than after AMI or
troke. In fact, a statistical test of heterogeneity of treatment
ffect was positive in the CAPRIE trial (p  0.042),
roviding statistical evidence of nonhomogeneity of the
reatment effect of clopidogrel as compared with aspirin
cross the three treatment arms (1). Thus, the usual as-
umption in a clinical trial, that differences in subgroup
reatment effects are caused by chance and are more likely
quivalent to the overall treatment effect, is likely invalid in
he CAPRIE study.
As with our representative patient, a number of patients
n the CAPRIE study had a history of other vascular events
efore the index event. A post-hoc secondary analysis was
erformed to compare patients with a history of MI. When
atients from the stroke and PAD groups with previous
MI were combined with the AMI group, the event rate for
lopidogrel was nonsignificantly lower than for aspirin
5.87% vs. 6.25%; RRR 7.4%; 95% confidence interval [CI]
5.2% to 18.6%). When patients from the stroke and PAD
roups who had suffered a previous MI were pooled, the
esults also favored clopidogrel (8.35% vs. 10.74%; RRR
2.7%; 95% CI 4.9% to 37.2%). However, a far higher
roportion of patients in the PAD group than in the stroke
roup had a previous MI (21% vs. 12%), which suggests that
his analysis disproportionately reflects results from the
AD group. The results for stroke patients with a history of
I were not separately reported, preventing a direct com-
arison with the representative patient (1). The adverse
vent profiles for clopidogrel and aspirin were similar, and
oth agents were relatively well tolerated (1).
The CURE study randomized 12,562 patients to aspirin,
lus either clopidogrel or placebo, within 24 h of the onset
f acute coronary syndromes without ST-segment elevation.
onfatal MI, stroke, or vascular death was the primary end
oint. Follow-up was 3 to 12 months. The clopidogrel plus
spirin combination significantly reduced composite out-
ome risk versus aspirin alone (9.3% vs. 11.4%; RRR 20%;
5% CI 10% to 28%; p  0.001). There was no significant
ifference with regard to stroke risk; however, the number of
trokes was small (75 [1.2%] vs. 87 [1.4%]) (2).
However, the clopidogrel plus aspirin combination also
Abbreviations and Acronyms
AMI  acute myocardial infarction
CAD  coronary artery disease
CI  confidence interval
CVD  cardiovascular disease
ER-DP extended-release dipyridamole
IR-DP  immediate-release dipyridamole
PAD  peripheral artery disease
RRR  relative risk reduction
TIA  transient ischemic attackignificantly increased the risk of major bleeding events c3.7% vs. 2.7%; RRR 38%; p  0.001) This excess of
ajor bleeding event risk attenuates the net benefit expected
rom clopidogrel plus aspirin.
The recently reported Management of Atherothrombosis
n High-risk Patients with Recent Transient Ischemic
ttack or Ischemic Stroke (MATCH) trial randomized
,599 patients with recent stroke or TIA and other vascular
isk factors (including diabetes or a previous stroke, MI, or
AD) to treatment with clopidogrel alone or clopidogrel
lus aspirin. The composite end point (ischemic stroke, MI,
ascular death, or rehospitalization for ischemic event) rate
ver a mean 17.5-month follow-up was 15.70% for the
ombination therapy versus 16.73% for clopidogrel alone, a
tatistically nonsignificant difference (RRR 6.4%, p 
.244). As in the CURE study, combination therapy (clo-
idogrel plus aspirin) was associated with a statistically
ignificantly higher risk of life-threatening bleeding epi-
odes than with clopidogrel alone (2.55% vs. 1.30%, respec-
ively; relative risk 1.96, p  0.001). There was also a
tatistically significant excess of other major (non–life-
hreatening) bleeding events for combination therapy versus
lopidogrel alone (1.94% vs. 0.58%; relative risk 3.34; p 
.001) As compared with the results of the CURE trial,
owever, the absolute increase in bleeding episodes associ-
ted with combination therapy was greater than the absolute
eduction in vascular events. Thus, in strong contrast to the
URE trial, the results of the MATCH trial suggest net
arm from the use of clopidogrel plus aspirin as compared
ith monotherapy in stroke and TIA patients (3).
Aspirin plus dipyridamole in combination was evaluated
nitially using an immediate-release dipyridamole (IR-DP)
ormulation (330 mg aspirin plus 75 mg dipyridamole three
imes daily) that showed significant benefit versus placebo in
he prevention of secondary stroke (4). The ER-DP in
ombination with aspirin (25 mg aspirin plus 200 mg
R-DP twice daily) has superseded IR-DP for this indica-
ion. The ER-DP formulation was developed to maintain
herapeutic blood concentrations with less frequent dosing
han was required of the IR-DP formulation (5).
The efficacy of aspirin plus ER-DP was evaluated in the
econd European Stroke Prevention Study (ESPS-2),
hich randomized 6,602 patients with previous stroke or
IA to treatment with aspirin alone, ER-DP alone, both
spirin and ER-DP, or placebo. Both aspirin and ER-DP
onotherapy reduced the risk of stroke versus placebo
aspirin: RRR 18%; p  0.013; ER-DP: RRR 16%, p 
.039), as well as the risk of a composite stroke or death
utcome (aspirin: RRR 13%; p  0.016; ER-DP: RRR
5%; p  0.015) (6).
In addition, the combination of aspirin plus ER-DP was
wice as efficacious as either agent alone. Specifically, aspirin
lus ER-DP reduced the relative risk of stroke by 23%
ompared with aspirin alone (p  0.001), and the relative
isk of stroke, MI, and sudden death by 20% compared with
spirin alone (p  0.005). These results suggest that the
ombination therapy provides a clinically, as well as statis-
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Secondary Stroke Prevention September 6, 2005:752–5ically, significant degree of additive benefit when compared
ith aspirin monotherapy (6). Importantly, unlike the
URE and MATCH trials, there were no statistically
ignificant differences in major or fatal bleeding events, or
astrointestinal bleeding events for the combination of
spirin plus ER-DP versus aspirin alone.
Regarding patients with a known history of CAD (such
s our case patient), 36% of patients in the ESPS-2 trial fell
nto this category, and an additional 10% had a history of
ongestive heart failure. For these patients, the benefit
ssociated with aspirin plus ER-DP for the prevention of
troke and death was as great as that observed in patients
ith no such history. The rate of MI was low in the ESPS-2
rial (2.5%) and was unaffected by the use of ER-DP.
spirin use resulted in a 21% RRR of MI in the study.
owever, this was not statistically significant because the
verall rate of MI was much lower than that of stroke in the
tudy.
All treatments in the ESPS-2 study were relatively well
olerated. In fact, more than 97% of patients treated with
R-DP (alone or with aspirin) were compliant, as evaluated
y serum assay. The most common adverse event associated
ith ER-DP was headache. Both all-site and gastroin-
estinal bleeding were significantly more frequent with
spirin (6).
TUDY COMPARISONS
t is possible to indirectly compare several aspects of the
tudies investigating clopidogrel (with or without aspirin)
nd aspirin plus ER-DP. Whereas the CAPRIE trial used
composite end point and enrolled patients with different
ndex vascular events, the CURE, MATCH, and ESPS-2
rial used more limited study populations, resulting in a
ore focused picture of the response to pharmacological
herapy in specific syndromes. Although this may help to
ncrease the statistical strength of results, it also limits the
bility to generalize them to broader groups of patients. On
he other hand, the design of the CAPRIE trial assumed a
road equivalence of clopidogrel efficacy in treating different
ascular events, but its results contradicted this concept,
howing a pronounced heterogeneity in treatment effective-
ess based on the nature of the index event. As shown
ompellingly by the results of the CURE and MATCH
rials, it is dangerous to assume that one can generalize
fficacy results from one vascular event population to an-
ther.
Similarly, the assumption of equivalent risk for recurrence
f different types of vascular events in patients with recent
troke and TIA as compared with patients with recent acute
oronary syndrome or MI is not supported by recent
vidence. A study of secondary events after AMI and stroke
as shown that the risk of recurrence of an event of the same
ype is three to five times greater than the risk of an event of
different type (7). In the CAPRIE study, the stroke groupxperienced recurrent strokes at a 6.87 times greater fre- duency than MI, and the AMI group experienced recurrent
MI at 4.01 times the stroke rate (1). Other recent trials
omparing antiplatelet therapies for secondary stroke pre-
ention have shown a 2.5- to 13-fold higher frequency of
trokes than MIs once a patient has suffered a stroke or TIA
6,8–10). Collectively, these data strongly suggest that
lthough similar risk factors underlie most forms of CVD,
ndividual patients are prone to events in specific vascular
eds. The most recent event seems to predict the next event,
specially in stroke patients. The MATCH trial results also
upport these observations. To put this into perspective, our
ase patient had suffered both an MI and a stroke, but
ecause the most recent event was stroke, the greatest risk
or recurrence would be for another stroke.
At this point, there have been few well-controlled,
ell-designed trials of combination regimens such as aspirin
lus clopidogrel or aspirin plus ER-DP for prevention of all
ascular events. However, several studies that address vari-
us aspects of secondary prevention are planned or in
rogress. The Clopidogrel for High Atherothrombotic Risk
nd Ischemic Stabilization, Management, and Avoidance
CHARISMA) trial is evaluating the efficacy of aspirin plus
lopidogrel, as compared with aspirin alone, in preventing
ascular events in patients who either have had a recent
ascular event or are at high risk for one. The latter group
ill provide an important first look at the efficacy and safety
f clopidogrel plus aspirin for primary prevention of vascular
vents in high-risk patients. The Secondary Prevention of
mall Subcortical Strokes (SPS3) trial is comparing aspirin
lus clopidogrel with aspirin alone in prevention of recur-
ent lacunar or small-vessel stroke, and the Antithrombotic
herapy in Acute Recovered cerebral Ischemia (ATARI)
tudy is comparing aspirin plus clopidogrel with aspirin
lone in TIA patients. The ongoing Atrial Fibrillation
lopidogrel Trial with Irbesartan for the Prevention of
ascular Events (ACTIVE) study is evaluating the efficacy
f clopidogrel in combination with the antihypertensive
gent irbesartan in 14,000 patients with atrial fibrillation
ver a four-year period.
The Prospective Regimen For Effectively avoiding Sec-
nd Strokes (PRoFESS) study will be the largest prospec-
ive secondary stroke prevention trial in history, enrolling
5,500 patients with a recent history of ischemic stroke in a
 2 factorial design. The PRoFESS study will provide the
rst head-to-head comparison between aspirin plus ER-DP
nd clopidogrel. Although the original study design in-
luded a comparison between aspirin plus ER-DP and
spirin plus clopidogrel, the Data Safety Monitoring Board
as eliminated aspirin from the aspirin plus clopidogrel arm
n light of results from the MATCH study. Each antiplate-
et regimen also will be evaluated with concurrent use of
elmisartan, an angiotensin II receptor blockade antihyper-
ensive agent. The primary end point is time to the first
ecurrent stroke, with a composite secondary end point
time to the first nonfatal stroke, nonfatal MI, or vascular
eath). Finally, the European/Australasian Stroke Preven-
t
o
w
v
C
P
n
c
E
o
s
r
a
f
w
t
o
s
i
c
i
c
u
l
p
d
t
b
p
a
R
2
E
R
1
755JACC Vol. 46, No. 5, 2005 Gebel, Jr.
September 6, 2005:752–5 Secondary Stroke Preventionion in Reversible Ischemia Trial (ESPRIT) is another
ngoing clinical trial comparing aspirin and dipyridamole
ith aspirin alone in TIA and stroke patients for recurrent
ascular event prevention.
ONCLUSIONS
ending the results of ongoing and planned studies, the limited
umber of available studies on the relative effectiveness of
ombination therapies based on clopidogrel and aspirin plus
R-DP makes it difficult to broadly recommend one in favor
f the other. Instead, a review of the currently published data
uggests the importance of focusing on the nature of the most
ecent vascular event and individualizing antiplatelet therapy
ccordingly. The evidence supporting aspirin and clopidogrel
or treating acute coronary syndrome patients is strong,
hereas what if any role aspirin plus ER-DP will play remains
o be defined. Conversely, the evidence supporting the efficacy
f aspirin plus ER-DP for secondary event prevention after
troke and TIA is strong, whereas data suggest that clopidogrel
s no more efficacious than aspirin and that the combination of
lopidogrel plus aspirin is probably harmful in this population.
Because between-study comparisons remain indirect, the
nterpretation outlined here may not be universally ac-
epted. However, results from the four major studies eval-
ating these combinations suggest that there is no compel-
ing reason to switch the representative patient from aspirin
lus ER-DP to aspirin plus clopidogrel (or even to clopi-
ogrel alone). Moreover, the MATCH study results suggest
hat a switch to clopidogrel plus aspirin would, if anything,
e harmful rather than beneficial. Thus, the representative
atient should be maintained on his current regimen of
spirin plus ER-DP.eprint requests and correspondence: Dr. James M. Gebel, Jr.,
50 East Liberty Street, Suite 500, Louisville, Kentucky 40202.
-mail: j.gebel@att.net.
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